Welcome to the website of INterface BIOmaterials B.V.

INterface BIOmaterials B.V. (founded in 2008) is an independent bioscience company with expertise in biomedical materials and medical devices. The company has a quality management system according to ISO 13485.

 

The company developed a proprietary new product for the embolization of uterine fibroids. The product, known as X-Spheres™, was CE certified in spring 2013.

The distinguishing unique feature of the X-Spheres™ is that the embolizing spherical microparticles are not only biocompatible but also radio-opaque. The spherical microparticles can be visualized through X-ray fluoroscopy, i.e. during the embolization procedure, and also afterwards. This feature will contribute to the efficacy and safety of embolization procedures.

X-Spheres syringe
X-Spheres™ containing the dispersed embolizing microparticles

 

X-ray rabbit kidney
Demonstration of the X-ray visibility of the embolizing microparticles; the microparticles were injected into a rabbit kidney.

 

 

  • Latest news:

    February 2015:

    PMLF laboratory technology/biotechnology accreditation

     

    February 2014:

    INterface BIOmaterials BV participates in the LSH impuls project: “KidneyPort

     

    August 2013:

    PMLF laboratory technology accreditation

     

    July 2013:

    PMLF process engineering accreditation

     

    February 2013:

    CE certification on X-Spheres™

     

    November 2012:

    ISO 13485 certification

     

    January 2011:

    INterface BIOmaterials BV participates in the Interreg IVa project: “BioMiMedics”

     

    January 2010:

    INterface BIOmaterials BV participates in the “iNephron” project subsidized by the Dutch Kidney Foundation